• Mission

    Spring Bank is devoted to pioneering its revolutionary SMNH chemistry platform to discover and develop a new generation of medicines to improve the lives of patients worldwide.
  • Our Technology

    Our proprietary small molecule nucleic acid hybrids (SMNH) chemistry platform produces a class of compounds designed to selectively target and modulate the activity of specific proteins implicated in various disease states with the favorable drug-like qualities of traditional small molecules.
  • Clinical Trials

    Get the latest information about our ongoing clinical trials.
    Details
  • Latest News

      • APRIL 14, 2015

      Spring Bank Pharmaceuticals to Present HBV and HCV Results with SB 9200 at EASL 2015

      MILFORD, Mass., April 13, 2015 – Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, today announced two poster presentations on SB 9200, its lead drug candidate for the treatment of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) infections, at The International Liver Congress™ 2015,

      Read more